Cosentyx (Secukinumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Browse Detail Report With TOC @ http://www.hexareports.com/report/cosentyx-secukinumab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023/details

Novartis is developing a novel, SC, fully-human, IL-17A mAb known as Cosentyx (secukinumab, previously known as AIN457) for multiple indications, including RA. It is currently in Phase III clinical trials for RA in various countries, including the US, EU, and Japan. It prevents inflammatory responses, as it neutralizes IL-17A, resulting in the prevention of bone loss. As of November 2014, Cosentyx is currently undergoing regulatory review for psoriasis and in development for uveitis, psoriatic arthritis, ankylosing spondylitis, and asthma.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Cosentyx including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Cosentyx for the top eight countries from 2013 to 2023.

- Sales...